{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:38:31Z","timestamp":1790195911504,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009968","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000}}],"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>As lymphatic filariasis (LF) programs move closer to established targets for validation elimination of LF as a public health problem, diagnostic tools capable of supporting the needs of the programs are critical for success. Known limitations of existing diagnostic tools make it challenging to have confidence that program endpoints have been achieved. In 2019, the World Health Organization (WHO) established a Diagnostic Technical Advisory Group (DTAG) for Neglected Tropical Diseases tasked with prioritizing diagnostic needs including defining use-cases and target product profiles (TPPs) for needed tools. Subsequently, disease-specific DTAG subgroups, including one focused on LF, were established to develop TPPs and use-case analyses to be used by product developers. Here, we describe the development of two priority TPPs for LF diagnostics needed for making decisions for stopping mass drug administration (MDA) of a triple drug regimen and surveillance. Utilizing the WHO core TPP development process as the framework, the LF subgroup convened to discuss and determine attributes required for each use case. TPPs considered the following parameters: product use, design, performance, product configuration and cost, and access and equity. Version 1.0 TPPs for two use cases were published by WHO on 12 March 2021 within the WHO Global Observatory on Health Research and Development. A common TPP characteristic that emerged in both use cases was the need to identify new biomarkers that would allow for greater precision in program delivery. As LF diagnostic tests are rarely used for individual clinical diagnosis, it became apparent that reliance on population-based surveys for decision making requires consideration of test performance in the context of such surveys. In low prevalence settings, the number of false positive test results may lead to unnecessary continuation or resumption of MDA, thus wasting valuable resources and time. Therefore, highly specific diagnostic tools are paramount when used to measure low thresholds. The TPP process brought to the forefront the importance of linking use case, program platform and diagnostic performance characteristics when defining required criteria for diagnostic tools.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009968","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T13:43:58Z","timestamp":1636983838000},"page":"e0009968","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Diagnostics to support elimination of lymphatic filariasis\u2014Development of two target product profiles"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-6140","authenticated-orcid":true,"given":"Kimberly Y.","family":"Won","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-8039","authenticated-orcid":true,"given":"Katherine","family":"Gass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6870-6283","authenticated-orcid":true,"given":"Marco","family":"Biamonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Argaw","family":"Dagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Ducker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Hoerauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2139-6564","authenticated-orcid":true,"given":"Patrick J.","family":"Lammie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-476X","authenticated-orcid":true,"given":"Sammy M.","family":"Njenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7583-0752","authenticated-orcid":true,"given":"Rahmah","family":"Noordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9607-7525","authenticated-orcid":true,"given":"Kapa D.","family":"Ramaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-2669","authenticated-orcid":true,"given":"Reda","family":"Ramzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-3912","authenticated-orcid":true,"given":"Ronaldo G. Carvalho","family":"Scholte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-6649","authenticated-orcid":true,"given":"Anthony W.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1971-8859","authenticated-orcid":true,"given":"Ashley A.","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5538-2067","authenticated-orcid":true,"given":"Jordan","family":"Tappero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Toubali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-3824","authenticated-orcid":true,"given":"Gary J.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4881-7496","authenticated-orcid":true,"given":"Steven A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"issue":"9747","key":"pntd.0009968.ref001","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(10)60586-7","article-title":"Lymphatic filariasis and onchocerciasis","volume":"376","author":"MJ Taylor","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"pntd.0009968.ref002","doi-asserted-by":"crossref","first-page":"i53","DOI":"10.1093\/inthealth\/ihv071","article-title":"Social stigma towards neglected tropical diseases: a systematic review","volume":"8","author":"K Hofstraat","year":"2016","journal-title":"Int Health"},{"issue":"43","key":"pntd.0009968.ref003","first-page":"509","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2019","volume":"95","author":"WHO","year":"2020","journal-title":"Weekly Epidemiological Record"},{"issue":"11","key":"pntd.0009968.ref004","doi-asserted-by":"crossref","first-page":"e3319","DOI":"10.1371\/journal.pntd.0003319","article-title":"Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease","volume":"8","author":"KD Ramaiah","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0009968.ref005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40249-016-0147-4","article-title":"The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000\u20132014)","volume":"5","author":"HC Turner","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"pntd.0009968.ref006","author":"WHO","year":"2020","journal-title":"Ending the neglect to attain the Sustainable Development Goals\u2014A road map for neglected tropical diseases 2021\u20132030"},{"key":"pntd.0009968.ref007","author":"WHO","year":"2017","journal-title":"Guideline\u2013Alternative mass drug administration regimens to eliminate lymphatic filariasis"},{"issue":"3","key":"pntd.0009968.ref008","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"19","key":"pntd.0009968.ref009","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A Trial of a Triple-Drug Treatment for Lymphatic Filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"N Engl J Med"},{"key":"pntd.0009968.ref010","author":"WHO","year":"2011","journal-title":"Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminate lymphatic filariasis: a manual for national elimination programmes"},{"issue":"20","key":"pntd.0009968.ref011","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMc1914262","article-title":"Single-Dose Triple-Drug Therapy for Wuchereria bancrofti\u20145-Year Follow-up","volume":"382","author":"CL King","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"pntd.0009968.ref012","doi-asserted-by":"crossref","first-page":"e1941","DOI":"10.1371\/journal.pntd.0001941","article-title":"Longitudinal monitoring of the development of antifilarial antibodies and acquisition of Wuchereria bancrofti in a highly endemic area of Haiti","volume":"6","author":"KL Hamlin","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0009968.ref013","doi-asserted-by":"crossref","first-page":"e0008298","DOI":"10.1371\/journal.pntd.0008298","article-title":"Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study","volume":"14","author":"CL Dubray","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0009968.ref014","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2883-3-9","article-title":"Recombinant antigen-based antibody assays for the diagnosis and surveillance of lymphatic filariasis\u2014a multicenter trial","volume":"3","author":"PJ Lammie","year":"2004","journal-title":"Filaria J"},{"issue":"1","key":"pntd.0009968.ref015","first-page":"191","article-title":"Duration of detection of anti-BmR1 IgG4 antibodies after mass-drug administration (MDA) in Sarawak, Malaysia","volume":"29","author":"R Noordin","year":"2012","journal-title":"Trop Biomed"},{"issue":"3","key":"pntd.0009968.ref016","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0035-9203(01)90234-2","article-title":"A recombinant antigen-based IgG4 ELISA for the specific and sensitive detection of Brugia malayi infection","volume":"95","author":"N Rahmah","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"12","key":"pntd.0009968.ref017","doi-asserted-by":"crossref","first-page":"e0008933","DOI":"10.1371\/journal.pntd.0008933","article-title":"Time for a diagnostic sea-change: Rethinking neglected tropical disease diagnostics to achieve elimination","volume":"14","author":"K Gass","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009968.ref018","unstructured":"WHO. Report of the first meeting of the WHO Diagnostic Technical Advisory Group for Neglected Tropical Diseases, Geneva, Switzerland, 30\u201331 October 2019. 2020."},{"key":"pntd.0009968.ref019","volume-title":"Quality Function Deployment and Six Sigma: A QFD Handbook","author":"JP Ficalora","year":"2010"},{"key":"pntd.0009968.ref020","volume-title":"Juran on Quality by Design: The New Steps for Planning Quality Into Goods and Services","author":"JM Juran","year":"1992"},{"issue":"11","key":"pntd.0009968.ref021","doi-asserted-by":"crossref","first-page":"e3281","DOI":"10.1371\/journal.pntd.0003281","article-title":"A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration","volume":"8","author":"RU Rao","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0009968.ref022","volume-title":"Diagnostic test for surveillance of lymphatic filariasis: target product profile","author":"WHO","year":"2021"},{"key":"pntd.0009968.ref023","volume-title":"Diagnostic test for lymphatic filariasis to support decisions for stopping triple-therapy mass drug administration: target product profile","author":"WHO","year":"2021"},{"issue":"2","key":"pntd.0009968.ref024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pt.2006.12.001","article-title":"Diagnostic tools for filariasis elimination programs","volume":"23","author":"GJ Weil","year":"2007","journal-title":"Trends Parasitol"},{"issue":"1","key":"pntd.0009968.ref025","doi-asserted-by":"crossref","first-page":"e1479","DOI":"10.1371\/journal.pntd.0001479","article-title":"A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis","volume":"6","author":"K Gass","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0009968.ref026","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0169-4758(97)01130-7","article-title":"The ICT Filariasis Test: A rapid-format antigen test for diagnosis of bancroftian filariasis","volume":"13","author":"GJ Weil","year":"1997","journal-title":"Parasitol Today"},{"issue":"6","key":"pntd.0009968.ref027","first-page":"491","article-title":"Strategies and tools for the control\/elimination of lymphatic filariasis","volume":"75","author":"EA Ottesen","year":"1997","journal-title":"Bull World Health Organ"},{"issue":"11","key":"pntd.0009968.ref028","doi-asserted-by":"crossref","first-page":"e0004184","DOI":"10.1371\/journal.pntd.0004184","article-title":"Cross-Reactivity of Filariais ICT Cards in Areas of Contrasting Endemicity of Loa loa and Mansonella perstans in Cameroon: Implications for Shrinking of the Lymphatic Filariasis Map in the Central African Region","volume":"9","author":"S Wanji","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0009968.ref029","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.4269\/ajtmh.16-0547","article-title":"Positivity of Antigen Tests Used for Diagnosis of Lymphatic Filariasis in Individuals Without Wuchereria bancrofti Infection But with High Loa loa Microfilaremia","volume":"95","author":"SD Pion","year":"2016","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0009968.ref030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4269\/ajtmh.17-0371","article-title":"Use of Antibody Tools to Provide Serologic Evidence of Elimination of Lymphatic Filariasis in The Gambia","volume":"98","author":"KY Won","year":"2018","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0009968.ref031","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0035-9203(03)90033-2","article-title":"Influence of infection with non-filarial helminths on the specificity of serological assays for antifilarial immunoglobulin G4","volume":"97","author":"AE Muck","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"Suppl 1","key":"pntd.0009968.ref032","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.actatropica.2010.04.010","article-title":"A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14","volume":"120","author":"GJ Weil","year":"2011","journal-title":"Acta Trop"},{"issue":"1","key":"pntd.0009968.ref033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13071-020-04535-y","article-title":"Assessment of the usefulness of anti-Wb123 antibody for post-elimination surveillance of lymphatic filariasis","volume":"14","author":"AM Dorkenoo","year":"2021","journal-title":"Parasit Vectors"},{"key":"pntd.0009968.ref034","author":"WHO","year":"2021","journal-title":"Onchocerciasis: diagnostic target product profile to support preventive chemotherapy"},{"key":"pntd.0009968.ref035","author":"WHO","year":"2021","journal-title":"Diagnostic target product profiles for monitoring, evaluation and surveillance of schistosomiasis control programmes"},{"key":"pntd.0009968.ref036","author":"WHO","year":"2021","journal-title":"Diagnostic target product profile for monitoring and evaluation of soil-transmitted helminth control programmes"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009968","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T14:07:54Z","timestamp":1638194874000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009968"}},"subtitle":[],"editor":[{"given":"Eileen","family":"Devaney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009968","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}